LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

Search

Pacific Biosciences of California Inc

Closed

SectorHealthcare

1.84 0.55

Overview

Share price change

24h

Current

Min

1.76

Max

1.8900000000000001

Key metrics

By Trading Economics

Income

3.9M

-38M

Sales

-1.3M

38M

Profit margin

-98.853

Employees

575

EBITDA

3.2M

-32M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+35.87% upside

Dividends

By Dow Jones

Next Earnings

7 maj 2026

Market Stats

By TradingEconomics

Market Cap

-117M

556M

Previous open

1.29

Previous close

1.84

Technical Score

By Trading Central

Confidence

Bullish Evidence

Pacific Biosciences of California Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 lut 2026, 23:57 UTC

Hot Stocks

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

12 lut 2026, 23:35 UTC

Earnings
Major Market Movers

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

12 lut 2026, 23:28 UTC

Earnings

Applied Materials Profit Rises on Soaring AI Demand -- Update

12 lut 2026, 21:47 UTC

Earnings

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

13 lut 2026, 00:00 UTC

Market Talk

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

12 lut 2026, 23:47 UTC

Market Talk

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

12 lut 2026, 23:38 UTC

Market Talk

Gold Steady; Could Undergo Technical Recovery -- Market Talk

12 lut 2026, 23:33 UTC

Earnings

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

12 lut 2026, 23:09 UTC

Market Talk

South32's Hermosa Review Stokes Spending Fears -- Market Talk

12 lut 2026, 22:55 UTC

Earnings
Hot Stocks

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

12 lut 2026, 22:46 UTC

Market Talk

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

12 lut 2026, 22:23 UTC

Earnings

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

12 lut 2026, 22:15 UTC

Earnings

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

12 lut 2026, 22:15 UTC

Earnings

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

12 lut 2026, 22:15 UTC

Earnings

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

12 lut 2026, 22:15 UTC

Earnings

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

12 lut 2026, 22:00 UTC

Earnings

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12 lut 2026, 22:00 UTC

Earnings

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

12 lut 2026, 22:00 UTC

Earnings

Agnico-Eagle Mines 4Q Net $1.52B >AEM

12 lut 2026, 22:00 UTC

Earnings

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

12 lut 2026, 22:00 UTC

Earnings

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12 lut 2026, 22:00 UTC

Earnings

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

12 lut 2026, 21:57 UTC

Earnings

XP 4Q Rev BRL4.95B >XP

12 lut 2026, 21:52 UTC

Earnings

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12 lut 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

12 lut 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

12 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 lut 2026, 21:47 UTC

Earnings

Morningstar 4Q Rev $641M >MORN

12 lut 2026, 21:39 UTC

Earnings

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12 lut 2026, 21:38 UTC

Earnings

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Peer Comparison

Price change

Pacific Biosciences of California Inc Forecast

Price Target

By TipRanks

35.87% upside

12 Months Forecast

Average 2.5 USD  35.87%

High 3 USD

Low 2 USD

Based on 4 Wall Street analysts offering 12 month price targets forPacific Biosciences of California Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

4 ratings

2

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

1.13 / N/ASupport & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
help-icon Live chat